- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07940231
Prospective Study of Intraoperative Brain Tumor Photographs for Pathological and Molecular Classification
Prospective Observational Validation of a Vision-Based Model for Integrated Histopathological and Molecular Classification of Gliomas From Intraoperative Specimen Photographs
This prospective observational cohort study will evaluate the diagnostic performance and workflow feasibility of a prespecified locked artificial intelligence model that analyzes smartphone-based natural-light gross images of fresh surgical tissue together with participant age. Approximately 400 consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will be enrolled at Beijing Tiantan Hospital, Capital Medical University, between July and September 2026. Images will be acquired before frozen-section processing according to a standardized operating procedure. Model outputs will be generated in silent mode and will not be shown to the surgical or pathology teams and will not alter diagnosis or treatment. The locked model score will be compared with the final IDH mutation reference standard derived from permanent histopathology, immunohistochemistry, and indicated molecular testing. The primary objective is to estimate patient-level discrimination for IDH-mutant versus IDH-wildtype tumors. Secondary objectives include fixed-threshold performance, precision-recall performance, calibration, end-to-end technical success, and prespecified model abstention, if an abstention rule is locked before enrollment.
Обзор исследования
Статус
Условия
Вмешательство/лечение
Подробное описание
Eligible participants will be enrolled consecutively, and a screening log will document all exclusions. Fresh ex vivo tumor tissue will be photographed before freezing. Images will be deidentified and linked through a participant-surgery-specimen-image hierarchy. The locked SNAP-IDH model will segment the tumor region of interest, permit blinded quality confirmation or editing, and combine frozen iBOT image features with age using a radial basis function support vector machine. The output is a research model score rather than a clinically calibrated absolute risk. A score of frozen yoden or will be classified as IDH-mutant. Model outputs will remain hidden from all clinical decision makers. No retraining, hyperparameter tuning, threshold selection, or recalibration will use the prospective cohort. Diagnostic accuracy will be analyzed at the participant level. Image-acquisition, segmentation, inference, and reference-standard failures will be retained in the study flow and reported separately from complete-case diagnostic performance.
Тип исследования
Регистрация (Оцененный)
Контакты и местонахождение
Контакты исследования
- Имя: Yinyan Wang
- Номер телефона: +86 13581698953
- Электронная почта: tiantanyinyan@126.com
Места учебы
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Китай
- Рекрутинг
- Beijing Tiantan Hospital
-
Контакт:
- Yinyan Wang
- Номер телефона: +86 13581698953
- Электронная почта: tiantanyinyan@126.com
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Метод выборки
Исследуемая популяция
Consecutive adults undergoing initial surgery for suspected intracranial adult diffuse glioma at the participating facility
Описание
Inclusion Criteria
- Adults aged 18 years or older at enrollment.
- A newly presenting intracranial lesion is radiologically suspected to be an adult-type diffuse glioma, and the participant is scheduled to undergo initial surgical resection or biopsy at a participating site.
- The planned index surgery includes an attempt to collect fresh tumor tissue for standardized natural-light gross-image acquisition before freezing.
- Participants must be able and willing to provide written informed consent before any study-specific procedure.
Exclusion Criteria
- Two or more radiologically distinct intracranial lesions identified on preoperative imaging.
- Radiotherapy or chemotherapy directed at the current intracranial lesion before the index surgery.
- Known recurrent disease or a previous tumor-directed surgical procedure for the current lesion.
- Primary spinal cord tumor, including a cervical spinal cord tumor.
Учебный план
Как устроено исследование?
Детали дизайна
- Наблюдательные модели: COHORT
- Временные перспективы: PROSPECTIVE
Когорты и вмешательства
Группа / когорта |
Вмешательство/лечение |
|---|---|
|
Prospective Silent-Validation Cohort. Consecutive adults undergoing initial surgery for suspected i
|
Consecutive adults undergoing initial surgery for suspected intracranial adult-type diffuse glioma will undergo standardized research imaging of fresh surgical tissue. Locked model outputs will not influence routine surgery, frozen-section assessment, permanent pathology, molecular testing, or treatment. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Patient-Level Area Under the Precision-Recall Curve of the Locked SNAP-IDH Score for IDH Mutation Status
Временное ограничение: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Area under the precision-recall curve (AUPRC) calculated using one locked SNAP-IDH score per patient and the final reference-standard isocitrate dehydrogenase (IDH) mutation status, with IDH-mutant status as the positive class. AUPRC ranges from 0 to 1, with higher values indicating better performance. |
From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Patient-Level Sensitivity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold
Временное ограничение: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-mutant status classified as IDH-mutant by SNAP-IDH at the prespecified, locked classification threshold. Sensitivity is calculated as true positives divided by the sum of true positives and false negatives, multiplied by 100. |
From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
|
Patient-Level Specificity of SNAP-IDH for IDH Mutation Status at the Prespecified Threshold
Временное ограничение: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Percentage of patients with reference-standard isocitrate dehydrogenase (IDH)-wildtype status classified as IDH-wildtype by SNAP-IDH at the prespecified, locked classification threshold. Specificity is calculated as true negatives divided by the sum of true negatives and false positives, multiplied by 100. |
From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
|
Patient-Level Brier Score of the Locked SNAP-IDH Predicted Probability for IDH Mutation Status
Временное ограничение: From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Mean squared difference between each patient's locked SNAP-IDH predicted probability of isocitrate dehydrogenase (IDH) mutation and the final reference-standard status, coded as 1 for IDH-mutant and 0 for IDH-wildtype. The Brier score ranges from 0 to 1, with lower values indicating lower prediction error. |
From intraoperative image acquisition until the final IDH reference standard is available, anticipated within 14 days after surgery.
|
Соавторы и исследователи
Спонсор
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
- Патологические процессы
- Новообразования
- Новообразования по гистологическому типу
- Новообразования железистые и эпителиальные
- Новообразования, нейроэпителиальные
- Нейроэктодермальные опухоли
- Новообразования, зародышевые клетки и эмбриональные
- Новообразования, нервная ткань
- Патологические состояния, признаки и симптомы
- Болезнь
- Глиома
Другие идентификационные номера исследования
- BT26901
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .